lncRNA TUG1 as potential novel biomarker for prognosis of cardiovascular diseases

Globally, cardiovascular diseases (CVDs) are among the leading causes of death. In light of the high prevalence and mortality of CVDs, it is imperative to understand the molecules involved in CVD pathogenesis and the signaling pathways that they initiate. This may facilitate the development of more precise and expedient diagnostic techniques, the identification of more effective prognostic molecules and the identification of potential therapeutic targets. Numerous studies have examined the role of lncRNAs, such as TUG1, in CVD pathogenesis in recent years. According to this review article, TUG1 can be considered a biomarker for predicting the prognosis of CVD.

Automated summary

Cardiovascular diseases (CVDs) are major causes of death worldwide. Understanding the molecular mechanisms and signaling pathways involved in CVD pathogenesis is crucial for the development of accurate diagnostic techniques, effective prognostic markers, and potential therapeutic targets. Recent research suggests that the lncRNA TUG1 can serve as a biomarker for predicting the prognosis of CVD.